ARGX:NSD-argenx SE (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 316.09

Change

0.00 (0.00)%

Market Cap

USD 16.22B

Volume

0.09M

Avg Analyst Target

USD 348.37 (+10.21%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD140.07B 233.80 177.21
BNTX BioNTech SE

N/A

USD68.10B 51.40 36.74
REGN Regeneron Pharmaceuticals, Inc

N/A

USD62.47B 16.69 13.10
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD51.90B 19.11 12.98
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

N/A

USD29.28B N/A N/A
GMAB Genmab A/S

N/A

USD29.00B 33.07 3.64
SGEN Seagen Inc

N/A

USD26.42B 40.63 36.27
RPRX Royalty Pharma plc

N/A

USD24.49B 33.25 14.58
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD21.44B N/A N/A

ETFs Containing ARGX

Symbol Name Weight Mer Price(Change) Market Cap
EWK iShares MSCI Belgium ETF 0.00 % 0.51 %

N/A

USD0.04B
AADR AdvisorShares Trust - Adv.. 0.00 % 1.10 %

N/A

USD0.09B
EXSD:F iShares STOXX Europe Mid .. 0.00 % 0.20 %

N/A

USD5,934.00B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.48% 68% D+ 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.48% 68% D+ 50% F
Trailing 12 Months  
Capital Gain 25.77% 68% D+ 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.77% 68% D+ 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 84.03% 86% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 84.03% 86% B 92% A-
Risk Return Profile  
Volatility (Standard Deviation) 98.67% 27% F 16% F
Risk Adjusted Return 85.16% 96% A 89% B+
Market Capitalization 16.22B 98% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.10 17% F 15% F
Price / Cash Flow Ratio -46.82 90% A- 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -43.80% 61% D- 31% F
Return on Invested Capital -35.04% 64% D 21% F
Return on Assets -15.96% 71% C- 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.90 46% F 32% F
Short Percent 1.75% 86% B 65% D
Beta 0.77 76% C 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector